Related Experiment Videos
Pneumococcal vaccine and otitis media
Insights
A pneumococcal polysaccharide vaccine reduced otitis media attacks in children over 6 months old. The vaccine showed 58% overall efficacy, with better results in children over 2 years old.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Otitis media is a common childhood infection.
- Pneumococcal bacteria are a leading cause of otitis media.
- Vaccine development aims to prevent bacterial infections.
Purpose of the Study:
- To evaluate the efficacy of a 14-valent pneumococcal polysaccharide vaccine in preventing otitis media in children.
- To assess antibody responses to pneumococcal polysaccharides in different age groups.
- To determine if previous otitis media attacks affect vaccine efficacy.
Main Methods:
- Randomized controlled trial involving 827 children aged 3 months to 6 years.
- Comparison between a 14-valent pneumococcal polysaccharide vaccine and a control vaccine (Haemophilus influenzae type b).
- Monitoring of otitis media attacks and serum antibody responses post-vaccination.
Main Results:
- Satisfactory antibody responses to most vaccine polysaccharides in children >6 months old, except for type 6A.
- No clinical protection observed below 6 months or against type 6 pneumococci.
- Significantly fewer otitis media attacks in vaccinated children (>6 months) caused by vaccine types (excluding 6A) compared to controls (p < 0.001).
- Statistically significant protection against type 19F (p < 0.01).
- Overall vaccine efficacy of 58%, higher in children >2 years old.
- Previous otitis media attacks did not impact vaccine efficacy.
Conclusions:
- The 14-valent pneumococcal polysaccharide vaccine is effective in preventing otitis media in children over 6 months of age.
- Vaccine efficacy varies by pneumococcal serotype and age group.
- Further research may be needed to improve protection against specific serotypes like 6A and in younger children.
Abstract:
After an acute attack of otitis media 827 children aged 3 months to 6 years were assigned randomly to receive either 14-valent pneumococcal polysaccharide vaccine or a control vaccine (Haemophilus influenzae type b capsular polysaccharide). In children older than 6 months serum antibody responses to most of the vaccine polysaccharides were satisfactory. The response to type 6A was poor. Correspondingly, no clinical protection was seen below 6 months of age or against otitis media caused by group 6 pneumococci. Among the children more than 6 months old, the first 6 months after vaccination saw significantly (p < 0.001) fewer attacks caused by the pneumococal types represented in the vaccine (group 6 excepted) in those who received the pneumococcal vaccine than in those who received the control vaccine. Protection against type 19F was statistically significant (p < 0.01). The overall protective efficacy was 58%--somewhat better in children older than 2 years than in those younger. Previous attacks of otitis caused by pneumococci did not influence the protective efficacy of the vaccine.